Department of Surgery, University of Helsinki and Helsinki University Hospital HUS, Haartmaninkatu 4, PO Box 440, FIN-00029, Helsinki, Finland.
Translational Cancer Medicine Research Program, Faculty of Medicine, University of Helsinki, Helsinki, Finland.
Virchows Arch. 2020 Nov;477(5):705-715. doi: 10.1007/s00428-020-02833-5. Epub 2020 May 19.
Colorectal cancer (CRC), the second most common cancer globally, resulted in 881,000 deaths in 2018. Toll-like receptors (TLRs) are crucial to detecting pathogen invasion and inducing the host's immune response. This study aimed to explore the prognostic value of TLR2 and TLR4 tumor expressions in colorectal cancer patients. We studied the immunohistochemical expressions of TLR2 and TLR4 using tissue microarray specimens from 825 patients undergoing surgery in the Department of Surgery, Helsinki University Hospital, between 1982 and 2002. We assessed the relationships between TLR2 and TLR4 expressions and clinicopathological variables and patient survival. We generated survival curves using the Kaplan-Meier method, determining significance with the log-rank test. Among patients with lymph node-positive disease and no distant metastases (Dukes C), a strong TLR2 immunoactivity associated with a better prognosis (p < 0.001). Among patients with local Dukes B disease, a strong TLR4 immunoactivity associated with a worse disease-specific survival (DSS; p = 0.017). In the multivariate survival analysis, moderate TLR4 immunoactivity compared with strong TLR4 immunoactivity (hazard ratio (HR) 0.66, 95% confidence interval (CI) 0.49-0.89, p = 0.007) served as an independent prognostic factor. In the multivariate analysis for the Dukes subgroups, moderate TLR2 immunoactivity (HR 2.63, 95% CI 1.56-4.44, p < 0.001) compared with strong TLR2 immunoactivity served as an independent negative prognostic factor in the Dukes C subgroup. TLR2 and TLR4 might be new prognostic factors to indicate which CRC patients require adjuvant therapy and which could spare from an unnecessary follow-up, but further investigations are needed.
结直肠癌(CRC)是全球第二大常见癌症,2018 年导致 88.1 万人死亡。Toll 样受体(TLR)在检测病原体入侵和诱导宿主免疫反应方面至关重要。本研究旨在探讨 TLR2 和 TLR4 肿瘤表达在结直肠癌患者中的预后价值。我们使用赫尔辛基大学医院外科部门 1982 年至 2002 年间接受手术的 825 名患者的组织微阵列标本,研究了 TLR2 和 TLR4 的免疫组织化学表达。我们评估了 TLR2 和 TLR4 表达与临床病理变量和患者生存之间的关系。我们使用 Kaplan-Meier 方法生成生存曲线,使用对数秩检验确定显著性。在淋巴结阳性疾病且无远处转移(Dukes C)的患者中,强烈的 TLR2 免疫活性与更好的预后相关(p<0.001)。在局部 Dukes B 疾病的患者中,强烈的 TLR4 免疫活性与较差的疾病特异性生存(DSS;p=0.017)相关。在多变量生存分析中,与强烈的 TLR4 免疫活性相比,中等强度的 TLR4 免疫活性(风险比(HR)0.66,95%置信区间(CI)0.49-0.89,p=0.007)是独立的预后因素。在 Dukes 亚组的多变量分析中,与强烈的 TLR2 免疫活性相比,中等强度的 TLR2 免疫活性(HR 2.63,95%CI 1.56-4.44,p<0.001)是 Dukes C 亚组的独立负预后因素。TLR2 和 TLR4 可能是新的预后因素,可以指示哪些 CRC 患者需要辅助治疗,哪些患者可以避免不必要的随访,但需要进一步研究。